The role of CD4+ T-cells in the development of MS

REFERENCES

• Liblau RS, Fontaine B. Recent advances in immunology in multiple sclerosis. Curr Opin Neurol 1998; 11: 293–298
   PubMed Web of Science ®Google Scholar
• Jacobson S. Association of human herpesvirus 6 and multiple sclerosis: Here we go again?J Neurovirol 1998; 4: 471–473
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransonhoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl.' Med 1998; 338: 278–285
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for pathogenesis of demyelination. Ann Neurol 2000; 47: 707–717
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl .1 Med 2000; 343: 938–952
   PubMed Web of Science ®Google Scholar
• Janeway C, Travers P, Walport M, Shlomchik M, eds. Immunobiology: The Immune System in Health and Disease, 5th edn, New York, NY: Garland Publishing, 2001
   Google Scholar
• Croxford JL, Olson JK, Miller SD. Epitope spreading and molecular mimicry as triggers of autoimmunity in the Theiler's virus-induced demyelinating disease model of multiple sclerosis. Autoimmun Rev 2002; 1: 251–260
   PubMedGoogle Scholar
• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153–187
   PubMed Web of Science ®Google Scholar
• Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579–621
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683–747
   PubMed Web of Science ®Google Scholar
• Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000; 12: 413–418
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547–549
   PubMed Web of Science ®Google Scholar
• Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–808
   PubMed Web of Science ®Google Scholar
• Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nature Immunol 2000; 1: 199–205
   PubMed Web of Science ®Google Scholar
• Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cells responses: The alternative approaches. Annu Rev Immunol 1997; 15: 297–322
   PubMed Web of Science ®Google Scholar
• Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45 (6 suppl. 6): S11—S15
   Google Scholar
• Panitch H, Hirsch RL, Haley AS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893–895
   PubMed Web of Science ®Google Scholar
• Martino G, Hartung HP. Immunopathogenesis of multiple sclero-sis: The role of T cells. Curr Opin Neurol 1999; 12: 309–321
   PubMed Web of Science ®Google Scholar
• Bonetti B, Raine CS. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997; 42: 74–84
   PubMed Web of Science ®Google Scholar
• Chofflon M, Roth S, Juilliard C, et al. Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis. Eur Cytokine Netw 1997; 8: 253–257
   PubMed Web of Science ®Google Scholar
• Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579–582
   PubMed Web of Science ®Google Scholar
• Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: A crucial re-appraisal. Trends Immunol 2004; 25: 132–137
   PubMed Web of Science ®Google Scholar
• Ufret-Vincenty RL, Quigley L, Tresser N, et al. In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis. I Exp Med 1998; 188: 1725–1738
   PubMed Web of Science ®Google Scholar
• Wekerle H, Hohlfeld R. Molecular mimicry in multiple sclerosis. N Engl J Med 2003; 349: 185–186
   PubMed Web of Science ®Google Scholar
• Bray PF, Luka J, Bray PF, et al. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992; 42: 1798–1804
   PubMed Web of Science ®Google Scholar
• Sheremata WA, Minagar A, Alexander JS, et al. The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs 2005; 19: 909–922
   PubMed Web of Science ®Google Scholar
• Gay FW, Drye TJ, Dick GW, et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120: 1461–1483
   PubMed Web of Science ®Google Scholar
• Raine CS, Cannella B, Hauser SL, et al. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144–160
   PubMed Web of Science ®Google Scholar
• Miller DJ, Njenga MK, Murray PD, et al. A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. Int Immunol 1996; 8: 131–141
   PubMed Web of Science ®Google Scholar
• Ciric B, Howe CL, Paz Soldan M, et al. Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003; 13: 608–616
   PubMed Web of Science ®Google Scholar
• Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: Structure, signaling, and roles in nervous system development and functions.] Neurochem 2000; 75: 2227–2240
   PubMed Web of Science ®Google Scholar
• Krieglstein K, Strelau J, Schober A, et al. TGF-beta and the regulation of neuronal survival and death.] Physiol Paris 2002; 96: 25–30
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan 0, Sheremata W, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Hardova F, et al. A randomized, placebo-controlled trial of natal izumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910
   PubMed Web of Science ®Google Scholar